Malignant B-lymphoid cells with bone lesions express receptor activator of nuclear factor-κB ligand and vascular endothelial growth factor to enhance osteoclastogenesis

Clinical Cancer Research

Volumn 11, Issue 17, 2005, Pages 6109-6115

  Shibata, Hironobu ^a   Abe, Masahiro ^a   Hiura, Kenji ^a   Wilde, Javier ^a   Moriyama, Keiji ^a   Sano, Toshiaki ^a   Kitazoe, Ken Ichi ^a   Hashimoto, Toshihiro ^a   Ozaki, Shuji ^b   Wakatsuki, Shingo ^c   Kido, Shinsuke ^a   Inoue, Daisuke ^a   Matsumoto, Toshio ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b TOKUSHIMA UNIVERSITY HOSPITAL   (Japan)

^c HYOGO PREFECTURAL AWAJI HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ARTICLE; B CELL LYMPHOMA; BONE DESTRUCTION; BONE LESION; BONE MARROW METASTASIS; CANCER CELL CULTURE; CANCER GROWTH; CANCER INFILTRATION; CELL INTERACTION; CELL MIGRATION; CELL STRAIN; CELL STRAIN IM 9; CELL STRAIN RAW265.7; CLINICAL ARTICLE; COCULTURE; DAUDI CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPHOMA CELL; MALIGNANT B LYMPHOID CELL; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; PREOSTEOCLAST; PRIORITY JOURNAL; STEM CELL; STROMA CELL;

BONE NEOPLASMS; CARRIER PROTEINS; CELL MOVEMENT; CULTURE MEDIA, CONDITIONED; FLOW CYTOMETRY; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHOMA, B-CELL; MEMBRANE GLYCOPROTEINS; OSTEOCLASTS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; STROMAL CELLS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 24344481288     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0181     Document Type: Article

References (40)

1. Suzuki A, Takahashi T, Okuno Y, et al. Production of parathyroid hormone-related protein by cultured human myeloma cells. Am J Hematol 1994;45:88-90.
2. Yamamoto I, Kawano M, Sone T, et al. Production of interleukin 1β, a potent bone resorbing cytokine, by cultured human myeloma cells. Cancer Res 1989;49: 4242-6.
3. Bataille R, Chappard D, Klein B. The critical role of interleukin-6, interleukin-1B and macrophage colony-stimulating factor in the pathogenesis of bone lesions in multiple myeloma. Int J Clin Lab Res 1992;21:283-7.
4. Abildgaard N, Glerup H, Rungby J, et al. Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma. Eur J Haematol 2000;64:121-9.
5. Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 1993;82:3712-20.
6. Abe M, Hiura K, Wilde J, et al. Role for macrophage inflammatory protein (MIP)-1α and MIP-1β in the development of osteolytic lesions in multiple myeloma. Blood 2002;100:2195-202.
7. Choi SJ, Oba Y, Gazitt Y, et al. Antisense inhibition of macrophage inflammatory protein 1-α blocks bone destruction in a model of myeloma bone disease. J Clin Invest 2001;108:1833-41.
8. Choi SJ, Cruz JC, Craig F, et al. Macrophage inflammatory protein 1-α is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000;96:671-5.
9. Han JH, Choi SJ, Kurihara N, Koide M, Oba Y, Roodman GD. Macrophage inflammatory protein-1α is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor κB ligand. Blood 2001;97:3349-53.
10. Hashimoto T, Abe M, Oshima T, et al. Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1α and MIP-1β correlates with lytic bone lesions in patients with multiple myeloma. Br J Haematol 2004;125:38-41.
11. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998; 95:3597-602.
12. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76.
13. Takahashi N, Udagawa N, Suda T. A new member of tumor necrosis factor ligand family, ODF/OPGL/ TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem Biophys Res Commun 1999; 256:449-55.
14. Nakagawa N, Kinosaki M, Yamaguchi K, et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 1998;253:395-400.
15. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.
16. Tsurukai T, Udagawa N, Matsuzaki K, Takahashi N, Suda T. Roles of macrophage-colony stimulating factor and osteoclast differentiation factor in osteoclastogenesis. J Bone Miner Metab 2000;18:177-84.
17. Niida S, Kaku M, Amano H, et al. Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. J Exp Med 1999;190:293-8.
18. Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 2001;98:3527-33.
19. Pearse RN, Sordillo EM, Yaccoby S, et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A 2001;98: 11581-6.
20. Seidel C, Hjertner O, Abildgaard N, et al. Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood 2001; 98:2269-71.
21. Sezer O, Heider U, Zavrski I, Kuhne CA, Hofbauer LC. RANK ligand and osteoprotegerin in myeloma bone disease. Blood 2003;101:2094-8.
22. Brown JM, Corey E, Lee ZD, et al. Osteoprotegerin and RANK ligand expression in prostate cancer. Urology 2001;57:611-6.
23. Giuliani N, Colla S, Sala R, et al. Human myeloma cells stimulate the receptor activator of nuclear factor-κB ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood 2002;100: 4615-21.
24. Nosaka K, Miyamoto T, Sakai T, Mitsuya H, Suda T, Matsuoka M. Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor κligand on adult T-cell leukemia cells. Blood 2002;99:634-40.
25. Kato I, Sato H, Kudo A. TRANCE together with IL-7 induces pre-B cells to proliferate. Eur J Immunol 2003; 33:334-41.
26. Sezer O, Heider U, Jakob C, et al. Immunocytochemistry reveals RANKL expression of myeloma cells. Blood 2002;99:4646-7, author reply 4647.
27. Heider U, Langelotz C, Jakob C, etal. Expression of receptor activator of nuclear factor κB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clin Cancer Res 2003;9:1436-40.
28. Farrugia AN, Atkins GJ, To LB, et al. Receptor activator of nuclear factor-κB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res 2003;63:5438-45.
29. Zhang J, Dai J, Qi Y, et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001;107:1235-44.
30. Brown JM, Corey E, Lee ZD, et al. Osteoprotegerin and RANK ligand expression in prostate cancer. Urology 2001;57:611-6.
31. Manabe N, Kawaguchi H, Chikuda H, et al. Connection between B lymphocyte and osteoclast differentiation pathways. J Immunol 2001;167:2625-31.
32. Choi Y, Woo KM, Ko SH, et al. Osteoclastogenesis is enhanced by activated B cells but suppressed by activated CD8(+) Tcells. Eur J Immunol 2001;31: 2179-88.
33. Tezuka K, Sato T, Kamioka H, et al. Identification of osteopontin in isolated rabbit osteoclasts. Biochem Biophys Res Commun 1992;186:911-7.
34. Quinn JM, Elliott J, Gillespie MT, Martin TJ. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology 1998;139:4424-7.
35. Kwon BS, Wang S, Udagawa N, et al. TR1, a new member of the tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption. FASEB J 1998;12:845-54.
36. Penno H, Silfversward CJ, Frost A, Brandstrom H, Nilsson O, Ljunggren O. Osteoprotegerin secretion from prostate cancer is stimulated by cytokines, in vitro. Biochem Biophys Res Commun 2002;293: 451-5.
37. Matsumoto Y, Tanaka K, Hirata G, et al. Possible involvement of the vascular endothelial growth factor-Flt-1-focal adhesion kinase pathway in chemotaxis and the cell proliferation of osteoclast precursor cells in arthritic joints. J Immunol 2002;168:5824-31.
38. Henriksen K, Karsdal MA, Delaisse JM, Engsig MT. RANKL and VEGF induce osteoclast chemotaxis through an ERK1/2 dependent mechanism. J Biol Chem 2003;278:48745-53.
39. Nagai M, Kyakumoto S, Sato N. Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation. Biochem Biophys Res Commun 2000;269:532-6.
40. Barcala V, Ruybal P, Garcia Rivello H, Waldner C, Ascione A, Mongini C. RANKL expression in a case of follicular lymphoma. Eur J Haematol 2003;70:417-9.